Intellia stock tumbles after pausing gene therapy trials on safety concerns
David A. Dunbar, President/CEO/Chairman of Standex International Corp (NYSE:SXI), sold 18,000 shares of common stock on October 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $235.00, for a total transaction value of $4.23 million. The sale comes as Standex shares trade near their 52-week high of $236.06, having surged over 73% in the past six months. According to InvestingPro analysis, the stock appears overvalued at current levels.
The sales were executed under a pre-arranged 10b5-1 trading plan dated November 22, 2024. Following the transactions, Dunbar indirectly holds 103,973 shares as Trustee of Trust and directly holds 1,429.9759 shares of Standex International. The company maintains strong financial health with a current ratio of 2.88 and has raised its dividend for 14 consecutive years. InvestingPro subscribers can access 15 additional investment tips and a comprehensive Pro Research Report for deeper analysis of Standex’s financial position.
In other recent news, Standex International Corporation reported a significant increase in revenue and operating margins for Q4 2025. This growth was driven by strong sales and operational efficiencies. The company’s strategic expansions and product innovations have contributed to this solid performance. These developments have positioned Standex well for future growth. The company’s stock closed at $225.88, reflecting a 1.82% increase. Investors reacted positively to the earnings report. Standex’s robust financial results highlight its effective business strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.